Pα+ Psychedelic Bulletin #217:
- Gilgamesh’s GM-1020 Prints Positive Topline
- FDA Lifts Hold on GH Research’s 5-MeO-DMT IND
- Compass Details Pivotal PTSD Trial Design
- Cybin Becomes Helus
- much more...
psychedelicalpha.com/news/p%ce%b1...
Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus…